251 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
Incyte Corp (INCY) Q1 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/04/30/incyte-corp-incy-q1-2019-earnings-call-transcript.aspx?source=iedfolrf0000001 Apr 30, 2019 - INCY earnings call for the period ending March 31, 2019.
Incyte Corporation (INCY) CEO Hervé Hoppenot on Q1 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4258062-incyte-corporation-incy-ceo-herve-hoppenot-q1-2019-results-earnings-call-transcript?source=feed_sector_healthcare Apr 30, 2019 - Incyte Corporation (NASDAQ:INCY) Q1 2019 Earnings Conference Call April 30, 2019 08:00 AM ET Company Participants Mike Booth - IR Hervé Hoppenot - CEO Barry Flannelly - EVP, General Manager, U.S. Stev
Incyte (INCY) Q1 Earnings & Revenues Beat Estimates, Up Y/Y http://www.zacks.com/stock/news/405929/incyte-incy-q1-earnings-revenues-beat-estimates-up-y-y?cid=CS-ZC-FT-405929 Apr 30, 2019 - While Incyte's (INCY) earnings and revenues beat estimates in Q1, Jakafi sales fall short of the same.
Is a Beat in the Cards for Incyte (INCY) in Q1 Earnings? http://www.zacks.com/stock/news/405363/is-a-beat-in-the-cards-for-incyte-incy-in-q1-earnings?cid=CS-ZC-FT-405363 Apr 29, 2019 - Incyte (INCY) is slated to report first-quarter results on Apr 30. Investors will primarily focus on Jakafi sales and pipeline updates.
What's in the Cards for Sarepta (SRPT) This Earnings Season? http://www.zacks.com/stock/news/404867/whats-in-the-cards-for-sarepta-srpt-this-earnings-season?cid=CS-ZC-FT-404867 Apr 29, 2019 - Sarepta Therapeutics' (SRPT) Exondys 51 likely to drive first-quarter sales.
Is a Beat in Store for Glaxo (GSK) This Earnings Season? http://www.zacks.com/stock/news/404550/is-a-beat-in-store-for-glaxo-gsk-this-earnings-season?cid=CS-ZC-FT-404550 Apr 26, 2019 - Strong sales of Glaxo's (GSK) Vaccines segment is likely to drive the top line in the first quarter.
What's in Store for Vertex (VRTX) This Earnings Season? http://www.zacks.com/stock/news/398972/whats-in-store-for-vertex-vrtx-this-earnings-season?cid=CS-ZC-FT-398972 Apr 24, 2019 - On Vertex's (VRTX) first-quarter earnings call, investor focus will be on its latest CF drug Symdeko's sales figure as well as the update on its CF triple-pill regimes.
What's in the Cards for Amarin (AMRN) This Earnings Season? http://www.zacks.com/stock/news/398903/whats-in-the-cards-for-amarin-amrn-this-earnings-season?cid=CS-ZC-FT-398903 Apr 24, 2019 - Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the first quarter.
Trevena (TRVN) to Post Q1 Earnings: What Awaits the Stock? http://www.zacks.com/stock/news/398878/trevena-trvn-to-post-q1-earnings-what-awaits-the-stock?cid=CS-ZC-FT-398878 Apr 24, 2019 - During Trevena's (TRVN) first-quarter 2019 conference call, investor focus will be on the company's progress to support its development of the pain therapy ??? oliceridine injection.
What's in the Cards for AstraZeneca (AZN) in Q1 Earnings? http://www.zacks.com/stock/news/392203/whats-in-the-cards-for-astrazeneca-azn-in-q1-earnings?cid=CS-ZC-FT-392203 Apr 23, 2019 - AstraZeneca (AZN) will report first-quarter results on Apr 26. New drugs likely to drive sales.

Pages: 1234567...26

<Page 2>